“As Janssen is a single-dose vaccine, it will play an important role in the months to come as we redouble our efforts to encourage everyone to get their jabs and potentially begin a booster programme later this year,” health minister Matt Hancock said.
The vaccine is part of a British study looking at whether giving third-dose booster COVID-19 shots could extend immune protection. read more
“The results of this will be important in determining how supplies of this vaccine can be best utilised when they arrive,” said Professor Arne Akbar, President of the British Society for Immunology, adding the approval would not have an immediate impact on rollout.
J&J’s vaccine had already been approved by the World Health Organization, the United States and the European Union, where reports of rare blood clots are being reviewed.
The shot uses similar viral vector technology to the Oxford-AstraZeneca vaccine, which has seen reports of similar clots.
British officials have advised that under-40s are offered an alternative to the AstraZeneca shot due to the link to clots, and guidance on how J&J’s shot is used will be issued before rollout begins later this year.